Dopa-decarboxylase inhibitor + dopamine precursor. ≥18yrs: Do not crush or chew. Patients not receiving levodopa: initially one Sinemet CR 50–200 tab twice daily, at intervals of at least 6 hrs.
SPID ®-Technology utilizes compartmentalization to enable sequential release of carbidopa and levodopa, offering a potential new approach for drug delivery in Parkinson’s disease treatment. "Levodopa ...
The FDA approved an oral extended-release formulation of levodopa and carbidopa known as IPX203 (Crexont) to treat Parkinson's disease, Amneal Pharmaceuticals announced Wednesday. The treatment is a ...
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.S. Food and Drug Administration approved INBRIJA™ for intermittent treatment of OFF episodes in ...
Expert Rev Neurother. 2009;9(7):929-940. Improvements in levodopa pharmacokinetics with the addition of entacapone were similar to that seen in healthy volunteers. In addition, Phase II trials ...
Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced drug delivery systems, today announced the positive results from the Company's pilot nonclinical ...
Researchers in Australia have created a biodegradable gel that delivers Parkinson’s medications through a single weekly shot, replacing the need for multiple daily pills. Injected just under the skin, ...
Table 1. Percentage of patients decreasing daily levodopa dose by 4–6 weeks after entacapone initiation in Phase III clinical trials as grouped by baseline daily levodopa dose and presence of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results